Author
@BiotechCH BiotechCH
Biotech podcast/community hub delivering clinical-readout and deal-flow analysis with mixed sentiment
Aggregates and analyzes biotech/pharma news—clinical trial r
trader score
-0.38
hit rate
23%
mean α
-0.35%
signals 14d
21
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 13 scored bets: 23% hit rate, -0.35% mean alpha, trader score -0.38.
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | JNJ | @BiotechCH | +0.50 | JNJ received a label expansion for Imaavy 16 months after approval. | — | tweet ↗ |
| 2026-08-28 | AMLX | @BiotechCH | +0.65 | AMLX raised over $500M following positive Phase 3 avexitide data. | — | tweet ↗ |
| 2026-08-28 | AZN | @BiotechCH | -0.60 | AZN's Phase 3 ATTR-CM trial failed and showed no combination benefit. | — | tweet ↗ |
| 2026-08-28 | EYPT | @BiotechCH | -0.50 | EYPT's wet-AMD therapy missed its Phase 3 primary endpoint despite favorable secondary signals. | · | tweet ↗ |
| 2026-08-28 | SMMT | @BiotechCH | +0.65 | Ivonescimab won China approval and delivered a Phase 3 biliary-cancer result. | — | tweet ↗ |
| 2026-08-28 | · | @BiotechCH | · | Compares declining U.S. INDs with near-doubling of China's Phase 1 trial count. | · | tweet ↗ |
| 2026-08-28 | · | @BiotechCH | · | Discusses the FDA commissioner nominee and questions her organizational qualifications. | · | tweet ↗ |
| 2026-08-28 | · | @BiotechCH | · | Views the FDA nominee as pro-innovation and supportive of faster regulatory reform. | · | tweet ↗ |
| 2026-08-28 | RVMD | @BiotechCH | +0.50 | The FDA approved RVMD's pancreatic-cancer drug this week. | — | tweet ↗ |
| 2026-08-28 | BNTX | @BiotechCH | -0.55 | BNTX announced it is halting its colorectal-cancer vaccine trial. | — | tweet ↗ |
| 2026-08-28 | MRK | @BiotechCH | +0.60 | The MRNA-MRK cancer-vaccine trial hit recurrence and metastasis-free survival endpoints. | — | tweet ↗ |
| 2026-08-28 | MRNA | @BiotechCH | +0.70 | The MRNA-MRK cancer-vaccine trial hit recurrence and metastasis-free survival endpoints. | — | tweet ↗ |
| 2026-08-28 | MRNA | @BiotechCH | +0.20 | Discusses XBI's positive trend and adverse benchmark effects from MRNA's influx. | — | tweet ↗ |
| 2026-08-28 | XBI | @BiotechCH | +0.35 | Discusses XBI's positive trend and adverse benchmark effects from MRNA's influx. | — | tweet ↗ |
| 2026-08-28 | · | @BiotechCH | · | Frames biotech's rally as M&A-driven, citing $138B and more than 30 large deals YTD. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.